The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

Cristian Massacesi, Chief Medical Officer van AstraZeneca (NASDAQ: AZN ), gaf aan dat de positieve uitkomst van het POTOMAC-onderzoek een belangrijke vooruitgang betekent, waardoor mogelijk meer ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Positive high-level results have been presented by AstraZeneca (LSE: AZN) from the POTOMAC Phase III trial.

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...

LONDON (dpa-AFX) - AstraZeneca Plc. (AZN, AZN.L) announced that results from the POTOMAC Phase III trial showed that one year of treatment with its Imfinzi (durvalumab), combined with standard ...